Beclin 1 and bcl-2 expressions in bladder urothelial tumors and their association with clinicopathological parameters

Pathology Research and Practice

Volumn 209, Issue 7, 2013, Pages 418-423

  Baspinar, Sirin ^a   Bircan, Sema ^a   Yavuz, Gulcan ^b   Kapucuoglu, Nilgun ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Artvin State Hospital   (Turkey)

Author keywords

Bcl 2; Beclin 1; Bladder urothelial tumor

Indexed keywords

BECLIN 1; PROTEIN BCL 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER GRADING; CANCER STAGING; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY;

BCL-2; BECLIN 1; BLADDER UROTHELIAL TUMOR;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84880040128     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.04.006     Document Type: Article

References (41)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46:765-781.
2. Ulus T., Yurtseven E., Cavdar S., Erginoz E., Erdogan M.S. The suitability of using death certificates as a data source for cancer mortality assessment in Turkey. Croat. Med. J. 2012, 53:480-485.
3. Reznikoff C.A., Sarkar S., Knut P.J., Burger M.S., Newton M.A. Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol. Oncol. 2000, 5:191-203.
4. Schulz W.A. Understanding urothelial carcinoma through cancer pathways. Int. J. Cancer 2006, 119(7):1513-1518.
5. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 2004, 6:463-477.
6. Lian J., Karnak D., Xu L. The Bcl-2-Beclin 1 interaction in (-)-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Autophagy 2010, 6:1201-1203.
7. Shintani T., Klionsky D.J. Autophagy in health and disease: a double-edged sword. Science 2004, 306:990-995.
8. Liang X.H., Jackson S., Seaman M., Brown K., Kempkes B., Hibshoosh H., Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402:672-676.
9. Zhou F., Yang Y., Xing D. Bcl-2 Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J. 2011, 278:403-413.
10. Eisenberg-Lerner A., Bialik S., Simon H.U., Kimchi A. Life and death partners: apoptosis autophagy and the cross-talk between them. Cell Death Differ. 2009, 16:966-975.
11. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., Packer M., Schneider M.D., Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
12. Shimizu S., Kanaseki T., Mizushima N., Mizuta T., Arakawa-Kobayashi S., Thompson C.B., Tsujimoto Y. Role of Bcl-2 family proteins in a nonapoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 2004, 6:1221-1228.
13. Chen Y., Lu Y., Lu C., Zhang L. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1alpha expression. Pathol. Oncol. Res. 2009, 15:487-493.
14. Miracco C., Cosci E., Oliveri G., Luzi P., Pacenti L., Monciatti I., Mannucci S., De Nisi M.C., Toscano M., Malagnino V., Falzarano S.M., Pirtoli L., Tosi P. Protein mRNA expression of autophagy gene beclin 1 in human brain tumours. Int. J. Oncol. 2007, 30:429-436.
15. Shen Y., Li D.D., Wang L.L., Deng R., Zhu X.F. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy 2008, 4:1067-1068.
16. Shi Y.H., Ding Z.B., Zhou J., Qiu S.J., Fan J. Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma. Autophagy 2009, 5:380-382.
17. Won K.Y., Kim G.Y., Lim S.J., Kim Y.W. Decreased Beclin-1 expression is correlated with the growth of the primary tumor in patients with squamous cell carcinoma and adenocarcinoma of the lung. Hum. Pathol. 2012, 43:62-68.
18. Ahn C.H., Jeong E.G., Lee J.W., Kim M.S., Kim S.H., Kim S.S., Yoo N.J., Lee S.H. Expression of beclin-1 an autophagy-related protein, in gastric and colorectal cancers. APMIS 2007, 115:1344-1349.
19. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. Tumours of the urinary system. Tumours of the Urinary System and Male Genital Organs 2004, 90-134. IARC Press, Lyon. 2nd ed. J.N. Eble, G. Sauter, J.I. Epstein, I.A. Sesterhenn (Eds.).
20. Sobin L.H., Wittekind C. TNM Classification of Malignant Tumours 2002, 199-202. Wiley-Liss, New York. 6th ed.
21. Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717-1721.
22. Reggiori F., Klionsky D.J. Autophagosomes Biogenesis from scratch. Curr. Opin. Cell Biol. 2005, 17:415-422.
23. Chen Y.B., Hou J.H., Feng X.Y., Chen S., Zhou Z.W., Zhang X.S., Cai M.Y. Decreased expression of Beclin 1 correlates with a metastatic phenotypic feature and adverse prognosis of gastric carcinomas. J. Surg. Oncol. 2012, 105:542-547.
24. Wu X.Y., Chen J., Cao Q.H., Dong M., Lin Q., Fan X.J., Xia Q., Chen Z.H., Liu Q., Wan X.B. Beclin 1 activation enhances chemosensitivity and predicts a favorable outcome for primary duodenal adenocarcinoma. Tumour Biol. 2012, (Epub ahead of print).
25. Aita V.M., Liang X.H., Murty V.V., Pincus D.L., Yu W., Cayanis E., Kalachikov S., Gilliam T.C., Levine B. Cloning and genomic organization of beclin 1 a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999, 59:59-65.
26. A. Erman, N. Resnik, R. Romih, Autophagic activity in the mouse urinary bladder urothelium as a response to starvation, Protoplasma. doi:10.1007/s00709-012-0387-5.
27. 3+ exposed and transformed human urothelial cells (UROtsa). Toxicol. Lett. 2010, 195:15-22.
28. Chai C.Y., Huang Y.C., Hung W.C., Kang W.Y., Chen W.T. Arsenic salts induce autophagic cell death and hypermethylation of DAPK promoter in SV-40 immortalized human uroepithelial cells. Toxicol. Lett. 2007, 173:48-56.
29. Huang Y., Hung W.C., Chye S.M., Chen W.T., Chai C.Y. Para-phenylenediamine-induced autophagy in human uroepithelial cell line mediated mutant p53 and activation of ERK signaling pathway. Toxicol. In Vitro 2011, 25:1630-1637.
30. Liu G.H., Zhong Q., Ye Y.L., Wang H.B., Hu L.J., Qin Z.K., Zeng M.S., Zeng B.H. Expression of beclin 1 in bladder cancer and its clinical significance. Int. J. Biol. Markers 2012, (Epub ahead of print). 10.5301/JBM.2012.9769.
31. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
32. Mizushima N. The pleiotropic role of autophagy: from protein metabolism to bactericide. Cell Death Differ. 2005, 12:1535-1541.
33. Tzai T.S., Chow N.H., Lin J.S., Yang W.H., Tong Y.C. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Anticancer Res. 1998, 18:4717-4721.
34. Wu T.T., Chen J.H., Lee Y.H., Huang J.K. The role of bcl-2 p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J. Urol. 2000, 163:758-760.
35. Nakopoulou L., Vourlakou C., Zervas A., Tzonou A., Gakiopoulou H., Dimopoulos M.A. The prevalence of bcl-2 p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum. Pathol. 1998, 29:146-154.
36. Shiina H., Igawa M., Urakami S., Honda S., Shirakawa H., Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J. Clin. Pathol. 1996, 49:395-399.
37. Bilim V., Tomita Y., Kawasaki T., Katagiri A., Imai T., Takeda M., Takahashi K. Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J. Natl. Cancer Inst. 1996, 88:686-688.
38. Li B., Kanamaru H., Noriki S., Yamaguchi T., Fukuda M., Okada K. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder. Urol. Res. 1998, 26:235-241.
39. Gonzalez-Campora R., Davalos-Casanova G., Beato-Moreno A., Garcia-Escudero A., Pareja Megia M.J., Montironi R., Lopez-Beltran A. BCL-2 TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Lett. 2007, 250:292-299.
40. Cao S.S., Su A.P., Du X.J., Li A., Hu W.M., Zhang Z.D., Tian B.L., Lu H.M., Ke N.W., He Z.P. The expressions and correlation of bcl-2 and Beclin-1 in pancreatic cancer. Sichuan Da Xue Xue Bao Yi Xue Ban 2012, 43:156-160.
41. Won K.Y., Kim G.Y., Kim Y.W., Song J.Y., Lim S.J. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum. Pathol. 2010, 41:107-112.